Peptides DB
Research-centric peptide and protocol reference hub
Study 29 of 38SS-31 literaturebiorxiv-preprint · RCT2026

Statistical analysis plan for the ‘Pharyngeal electrical stimulation for acute stroke dysphagia trial’ (PhEAST) (ISRCTN98886991)

The PhEAST trial is investigating pharyngeal electrical stimulation for dysphagia in stroke patients, but results are not yet available.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the ss-31 corpus
4
Preclinical
26
Observational
0
Open-label
3
Randomised · this one
5
Reviews

Summary and findings

The study presents a statistical analysis plan for the PhEAST trial, which investigates pharyngeal electrical stimulation (PES) in 650 participants with tube-dependent post-stroke dysphagia. Participants are randomized to receive PES or no PES in addition to standard care, with PES administered daily for 6 days. The primary outcome is the dysphagia severity rating scale (DSR.S) assessed at days 14 and 90.

How much of this paper we could read: partial text (0.50). We had some abstract detail. Check the source for anything decisive. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>ABSTRACT</h4> <h4>Introduction</h4> Post stroke dysphagia is common, associated with poor functional outcome and lacks treatment strategies beyond behaviour therapies delivered by speech & language therapists. Here, we present the statistical analysis plan for the ongoing pharyngeal electrical stimulation for acute stroke dysphagia trial (PhEAST). PES is a candidate treatment for dysphagia present in non-ventilated stroke patients. <h4>Methods</h4> PhEAST is an investigator-initiated international prospective randomised open-label blinded-endpoint phase-4 superiority trial involving 650 participants with tube-dependent post-stroke dysphagia. Consenting patients are randomised to PES versus no PES given on top of standard care with PES given daily for 6 days. The primary outcome is the dysphagia severity rating scale (DSR.S), a measure of swallowing impairment, made at days 14 and 90 and analysed using repeated measures regression. <h4>Conclusion</h4> We present the statistical analysis plan for the main analyses based on data up to day 90 along with planned secondary analyses including presentation of baseline data, health economics, cognition and extended follow-up to 12 months.

Elsewhere in the SS-31 corpus

CStructural and functional characterisation of the dextran utilisome from &lt;i&gt;Bacteroides thetaiotaomicron&lt;/i&gt;.Journal of structural biology: X · 2026 · Not reported in abstract.In vitroC4-oxo-quinoline based fluorescent chemosensors for on-site detection of G-type nerve agent mimic DCP via spectroscopic and theoretical insights.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2026 · Limit of detection for DCP: 0.14 μM for 6DEQA.In vitroDEffectiveness of virtual reality-based rehabilitation on quality of life and upper extremity functions among stroke survivors: A systematic review and meta-analysis.International journal of nursing studies advances · 2026 · SMD = -0.09, 95% CI -0.30 to 0.11, p = .36; low certainty for QoL.reviewBKidney failure risk equation and early renal risk in adults with sickle cell disease: comparison with KDIGO classification using measured GFR.Renal failure · 2026 · 35.7% of participants had moderate-to-high KDIGO renal risk.HumanBAssociation of basal metabolic rate with mortality among cancer survivors: a cohort study emphasizing heterogeneity by gender and age.Annals of medicine · 2026 · Higher BMR was associated with reduced prevalence of all-cause mortality in older survivors aged ≥60 years.HumanBAssessing health beliefs and patient delay among breast cancer patients in West Sumatra, Indonesia.MethodsX · 2026 · Cronbach's α: 0.809-0.871 for the final tool.Human